Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Well being Group classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
Tang YT, Wang D, Luo H, Xiao M, Zhou HS, Liu D, et al. Aggressive NK-cell leukemia: scientific subtypes, molecular options, and therapy outcomes. Blood Most cancers J. 2017;7:660.
Fujimoto A, Ishida F, Izutsu Okay, Yamasaki S, Chihara D, Suzumiya J, et al. Allogeneic stem cell transplantation for sufferers with aggressive NK-cell leukemia. Bone Marrow Transpl. 2021;56:347–56.
Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive pure killer-cell leukemia revisited: giant granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.
Huang L, Liu D, Wang N, Ling S, Tang Y, Wu J, et al. Built-in genomic evaluation identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018;28:172–86.
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, et al. Aggressive pure killer-cell leukemia mutational panorama and drug profiling spotlight JAK-STAT signaling as therapeutic goal. Nat Commun. 2018;9:1567.
de Mel S, Hue SSS, Jeyasekharan AD, Chng WJ, Ng SB. Molecular pathogenic pathways in extranodal NK/T cell lymphoma. J Hematol Oncol. 2019;12:33.
Kameda Okay, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, et al. The hepatic area of interest results in aggressive pure killer cell leukemia proliferation by way of the transferrin-transferrin receptor 1 axis. Blood. 2023;142:352–64.
Ogama Y, Kumagai Y, Komatsu N, Araki M, Masubuchi N, Akiyoshi H, et al. Part 1 scientific trial of PPMX-T003, a novel human monoclonal antibody particular for transferrin receptor 1, to guage its security, pharmacokinetics, and pharmacodynamics. Clin Pharm Drug Dev. 2023;12:579–87.
Andreini C, Putignano V, Rosato A, Banci L. The human iron-proteome. Metallomics. 2018;10:1223–31.
Pham LT, Peng H, Ueno M, Kohno S, Kasada A, Hosomichi Okay, et al. RHEB is a possible therapeutic goal in T cell acute lymphoblastic leukemia. Biochem Biophys Res Commun. 2022;621:74–9.
Lifschitz S, Haeusler EH, Catanho M, Miranda AB, de Armas EM, de Heine A, et al. Bio-strings: a relational database data-type for coping with giant biosequences. BioTech (Basel). 2022;11:31.
Liao Y, Smyth GK, Shi W. The R bundle Rsubread is simpler, quicker, cheaper and higher for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47.
Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, et al. Software program for computing and annotating genomic ranges. PLoS Comput Biol. 2013;9:e1003118.
Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK permits sturdy identification of important genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a versatile trimmer for Illumina sequence knowledge. Bioinformatics. 2014;30:2114–20.
Kovaka S, Zimin AV, Pertea GM, Razaghi R, Salzberg SL, Pertea M. Transcriptome meeting from long-read RNA-seq alignments with StringTie2. Genome Biol. 2019;20:278.
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: utilizing gene-expression signatures to attach small molecules, genes, and illness. Science. 2006;313:1929–35.
Ushijima M, Mashima T, Tomida A, Dan S, Saito S, Furuno A, et al. Improvement of a gene expression database and associated evaluation applications for analysis of anticancer compounds. Most cancers Sci. 2013;104:360–8.
Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa Okay, Furuno A, et al. Complete transcriptomic evaluation of molecularly focused medicine in most cancers for goal pathway analysis. Most cancers Sci. 2015;106:909–20.
Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Built-in evaluation of multimodal single-cell knowledge. Cell. 2021;184:3573–87.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a common enrichment instrument for deciphering omics knowledge. Innovation (Camb). 2021;2:100141.
Shimizu T, Nakamura T, Inaba H, Iwasa H, Maruyama J, Arimoto-Matsuzaki Okay, et al. The RAS-interacting chaperone UNC119 drives the RASSF6–MDM2–p53 axis and antagonizes RAS-mediated malignant transformation. J Biol Chem. 2020;295:11214–30.
Luo W, Brouwer C. Pathview: an R/Bioconductor bundle for pathway-based knowledge integration and visualization. Bioinformatics. 2013;29:1830–1.
Novita Sari I, Setiawan T, Seock Kim Okay, Toni Wijaya Y, Gained Cho Okay, Younger Kwon H. Metabolism and performance of polyamines in most cancers development. Most cancers Lett. 2021;519:91–104.
Kanai Y. Amino acid transporter LAT1 (SLC7A5) as a molecular goal for most cancers analysis and therapeutics. Pharm Ther. 2022;230:107964.
Xu Q, Liu Y, Solar W, Track T, Jiang X, Zeng Okay, et al. Blockade LAT1 mediates methionine metabolism to beat oxaliplatin resistance beneath hypoxia in renal cell carcinoma. Cancers (Basel). 2022;14:2551.
Kanai Y, Hediger MA. The glutamate/impartial amino acid transporter household SLC1: molecular, physiological and pharmacological elements. Pflug Arch. 2004;447:469–79.
Okunushi Okay, Furihata T, Morio H, Muto Y, Higuchi Okay, Kaneko M, et al. JPH203, a newly developed anti-cancer drug, reveals a preincubation inhibitory impact on L-type amino acid transporter 1 perform. J Pharm Sci. 2020;144:16–22.
Wang L, Li X, Mu Y, Lu C, Tang S, Lu Okay, et al. The iron chelator desferrioxamine synergizes with chemotherapy for most cancers therapy. J Hint Elem Med Biol. 2019;56:131–8.
Kim JL, Lee DH, Na YJ, Kim BR, Jeong YA, Lee SI, et al. Iron chelator-induced apoptosis by way of the ER stress pathway in gastric most cancers cells. Tumour Biol. 2016;37:9709–19.
Kinoshita N, Gessho M, Torii T, Ashida Y, Akamatsu M, Guo AK, et al. The iron chelator deferriferrichrysin induces paraptosis by way of extracellular signal-related kinase activation in most cancers cells. Genes Cells. 2023;28:653–62.
Babosova O, Kapralova Okay, Raskova Kafkova L, Korinek V, Divoky V, Prchal JT, et al. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma’s cyclin D1. J Cell Mol Med. 2019;23:7785–95.
Vazana-Barad L, Granot G, Mor-Tzuntz R, Levi I, Dreyling M, Nathan I, et al. Mechanism of the antitumoral exercise of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymphoma. 2013;54:851–9.
Choi JG, Kim JL, Park J, Lee S, Park SJ, Kim JS, et al. Results of oral iron chelator deferasirox on human malignant lymphoma cells. Korean J Hematol. 2012;47:194–201.
Benadiba J, Rosilio C, Nebout M, Heimeroth V, Neffati Z, Popa A, et al. Iron chelation: an adjuvant remedy to focus on metabolism, progress and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2017;58:1433–45.
Chang YC, Lo WJ, Huang YT, Lin CL, Feng CC, Lin HT, et al. Deferasirox has robust anti-leukemia exercise however could antagonize the anti-leukemia impact of doxorubicin. Leuk Lymphoma. 2017;58:1–12.
O’Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, et al. Activation of transferrin receptor 1 by c-Myc enhances mobile proliferation and tumorigenesis. Mol Cell Biol. 2006;26:2373–86.
Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 Mechanisms of posttranscriptional regulation of the common cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood. 2007;110:752–61.
Okano N, Naruge D, Kawai Okay, Kobayashi T, Nagashima F, Endou H, et al. First-in-human section I examine of JPH203, an L-type amino acid transporter 1 inhibitor, in sufferers with superior strong tumors. Accessible from: https://doi.org/10.1007/s10637-020-00924-3.
